Bursa De Valori Bucuresti · BVB:BVB
Bursa De Valori Bucuresti — MedLife — H1 2023 Earnings Presentation
14 slides from Bursa De Valori Bucuresti's earnings presentation, Aug 25, 2023
Slide 1: H1 2023 Financial Results Presentation
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies SISTEMUL MEDICAL H1 2023 Financial Results Presentation 25 August 2023 www.medlife.ro / www.medlifeinternational.com
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 Highlights 6m 2023 • Key messages and outlook 2 AGENDA • Consolidated Statement of Profit and Loss Financial overview • • Consolidated Statement of Profit and Loss Financial overview • Consolidated Statement of Financial Position Consolidated Statement of Financial Position • Consolidated Statemen
Slide 4: Highlights 6m 2023
Highlights 6m 2023 • Key messages and Outlook 1 4/
Slide 5: Key messages and outlook
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Key messages and outlook ➢ first semester characterized by good performance across all business lines, with a 27% increase in revenues compared to H1 2022; ➢ Robust organic growth of 12% despite still difficult
Slide 6: Key messages and outlook (H2 outlook)
hyper clinics | hospitals | maternities | laboratories | excellence centers | pharma cies Key messages and outlook H2 outlook: ➢ Focus on consolidating the largest network of private medical services in Romania by continuing organic projects, with an emphasis on the expansion of hospital units in se
Slide 7: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 7/
Slide 8: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss 6m 2023 Pro-forma vs. 6m 2022 IFRS ❑ Gross Sales (National Health Program for chemotherapy drugs included) increased by 27%, reaching RON 1.09 bn for 6m 2023; ❑ Net Sales (net of drugs) increased by 20%, reaching RON 1.02bn; ❑ OPEX increased by 23%, to RON 9
Slide 9: Profit and Loss (Cont.): Operational KPIs by business line
Consolidated Statement of Profit and Loss (Cont.) Operational KPIs –business lines evolution ❑ Clinics remain the main sales unit of the group, with 37.3% share in total Sales: growth explained by sustained demand of outpatient medical services and new acquisitions performed during 2022 and 2023; +
Slide 10: Profit and Loss (Cont.): OPEX evolution
Consolidated Statement of Profit and Loss (Cont.) OPEX evolution Drivers for increased costs: ❑ Increase in Consumable materials and repair materials with 1.3 p.p. of Sales following NeoLife & Oncocard consolidation of chemotherapy drugs consumables; ❑ Decrease in Commodities with 1.8 p.p. of Sales
Slide 11: Financial Position
Consolidated Statement of Financial Position 1. About us 11 2. Highlights Q1 2023 3. Financial overview
Slide 12: Financial Position (Cont.): Debt position
Consolidated Statement of Financial Position (Cont.) Debt position 1. About us 12 2. Highlights Q1 2023 3. Financial overview
Slide 13: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow ❑ robust cash flow from operations before working capital changes at RON 139m; ❑ decrease in investments in 2023 compared to 2022, with RON 60m invested in business combinations and RON 73m in organic development projects; ❑ Net cash from financing activities of R
Slide 14: Q&A Session - Thank you!
Q&A Session Thank you! 3 14 /